Peptide · Agonist of Glucagon-like peptide-1 receptor (GLP1R) · developed by Astrazeneca
ApprovedFDA, Apr 2005
1Registered trials
What is Exenatide?
Exenatide is a peptide that partly overlaps the sequence of human GLP-1 and binds and activates the GLP-1 receptor. It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion and slows gastric emptying. It is studied in type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Byetta, AC-002993, AC-2993, AC-2993A
Drug type
Peptide
Targets
Glucagon-like peptide-1 receptor (GLP1R)
Mechanism
Agonist of Glucagon-like peptide-1 receptor (GLP1R)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.